Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
100084992 | 10008499 | 2 | F | 20140325 | 20140313 | 20140331 | EXP | JP-ELI_LILLY_AND_COMPANY-JP201403001486 | ELI LILLY AND CO | 65.00 | YR | M | Y | 0.00000 | 20140330 | N | CN | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
100084992 | 10008499 | 1 | PS | Gemcitabine Hydrochloride | 1 | INTRAVENOUS | 1000 MG/M2, UNK | D | 20509 | 1000 | MG/M**2 | ||||||||
100084992 | 10008499 | 2 | C | CISPLATIN | 1 | INTRAVENOUS | 36 MG/M2, UNK | D | 0 | 36 | MG/M**2 | ||||||||
100084992 | 10008499 | 3 | C | TS 1 | 1 | UNKNOWN | 100 MG, UNK | D | 0 | 100 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
100084992 | 10008499 | 1 | Gallbladder cancer stage IV |
100084992 | 10008499 | 2 | Gallbladder cancer stage IV |
100084992 | 10008499 | 3 | Gallbladder cancer stage IV |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
100084992 | 10008499 | OT |
100084992 | 10008499 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
100084992 | 10008499 | Decreased appetite | |
100084992 | 10008499 | Hypercalcaemia | |
100084992 | 10008499 | Leukocytosis | |
100084992 | 10008499 | Pulmonary embolism |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |